(IN BRIEF) Researchers at the University of Leicester have developed a groundbreaking treatment for severe asthma using the monoclonal antibody tezepelumab. This monthly injection targets thymic stromal lymphopoietin (TSLP), a substance associated with inflammation in the airways of severe asthma … Read the full press release
(PRESS RELEASE) CAMBRIDGE, 13-Jan-2023 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced that its drug Tezspire (tezepelumab) has been given the green light for self-administration by the European Medicine Agency’s Committee for Medicinal … Read the full press release
Posted in European Union, Healthcare, News, Pharma & Biotech, Science, Sweden, Technology, United Kingdom
Tagged allergic, asthma, asthma biologic, AstraZeneca, convenient pre-filled pen, EMA, eosinophilic, EU approval, Mene Pangalos, Professor Ian Pavord, self-administration, severe asthma patients, tezepelumab, Tezspire, University of Oxford
(COMUNICADO DE PRENSA) CAMBRIDGE, 13-Jan-2023 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), una multinacional británica-sueco-farmacéutica y biotecnológica, ha anunciado que su fármaco Tezspire (tezepelumab) ha recibido luz verde para la autoadministración por parte del Comité de Medicamentos de Uso Humano (CHMP) … Read the full press release
Posted in European Union, Healthcare, News, Pharma & Biotech, Science, Sweden, Technology, United Kingdom
Tagged alérgica, aprobación de la UE, asma, asma biológica, AstraZeneca, autoadministración, EMA, eosinofílica, Mene Pangalos, pacientes con asma grave, pluma precargada conveniente, profesor Ian Pavord, tezepelumab, Tezspire, Universidad de Oxford
AstraZeneca’s first Breakthrough Therapy Designation for a respiratory medicine Designation based on Phase IIb PATHWAY data that demonstrated tezepelumab significantly reduced asthma exacerbations compared to placebo in severe asthma CAMBRIDGE, 12-Sep-2018 — /EuropaWire/ — AstraZeneca and its partner Amgen Inc. (Amgen) … Read the full press release
Posted in Healthcare, Pharma & Biotech
Tagged Amgen, asthma, AstraZeneca, breakthrough therapy designation, eosinophilic_phenotype, medicine, respiratory, Sean Bohen, tezepelumab
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
